REPL
Same movie, worse sequel
Replimune just took a 57% gut punch after the FDA said no — again — to its melanoma treatment. In biotech, a rejection is bad. A second rejection is the kind that makes investors start checking the exit doors.
Why this matters
The drug at the center of the drama is RP1, also called vusolimogene oderparepvec, used in combination with nivolumab for advanced melanoma. The market was already twitchy after the first setback, so this latest rejection basically confirms the FDA is not interested in handing Replimune a happy ending anytime soon.
Wall Street’s mood swing
The headline also came with a downgrade, which is the financial equivalent of a friend saying, “I’m not mad, just disappointed.” When a drug story loses regulatory momentum, the stock often loses more than confidence — it loses the valuation fairy dust biotech lives on.
Big picture
For investors, this is the painful reminder that in biotech, the FDA can be the biggest shareholder in the room. And right now, it’s voting no.